Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

@article{Lode2013VaccinationWA,
  title={Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response},
  author={Holger N Lode and Manuel Schmidt and Diana Seidel and Nicole Huebener and Diana Brackrock and Matthias Bleeke and Daniel Reker and Sven Brandt and Hans-Peter Mueller and Christiane A. Helm and Nikolai Siebert},
  journal={Cancer Immunology, Immunotherapy},
  year={2013},
  volume={62},
  pages={999-1010}
}
PurposeImmunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric malignancy characterized by poor outcome. Here, we report the induction of a GD2-specific immune response with ganglidiomab, a new anti-idiotype antibody to anti-GD2 antibodies of the 14.18 family.Experimental design and resultsGanglidiomab was generated following immunization of Balb/c mice with 14G2a, and splenocytes were harvested to generate hybridoma cells. Clones… 
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
TLDR
Generation and characterization of a new human/mouse chimeric anti-Id Ab ganglidiximab for active immunotherapy against NB and this Ab may be useful to tailor immune responses to the paratope regions mimicking GD2 overexpressed in NB.
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Human/mouse chimeric monoclonal antibody (mAb) ch14.18 is directed against disialoganglioside GD2 and has demonstrated activity and efficacy in high-risk neuroblastoma (NB). For the purpose of
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
TLDR
The data suggest that recognition of GD2 by the chimeric receptor is the primary mechanism involved in NK-92-scFv(ch14.18)-zeta-mediated lysis and is independent of activating NK cell receptor/ligand interactions.
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients
TLDR
Evaluated the induction of Ab-dependent cell-mediated cytotoxicity (ADCC) in NSCLC patients included in a phase III clinical trial, in response to vaccination with racotumomab, demonstrating that anti-NeuGcGM3 Abs induced by racotomomab vaccination are able to mediate an antigen-specific ADCC response against tumor cells in NSclC patients.
Induction of protective and therapeutic anti-cancer immunity by using bispecific anti-idiotype antibody G22-I50 for nasopharyngeal carcinoma.
TLDR
The bispecific anti-idiotype antibody vaccine G22-I50 can induce strong humoral and cell-mediated immune responses and can be potentially applied to prevent and treat nasopharyngeal carcinoma.
Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
TLDR
A validated ELISA method suitable for the assessment of HACA in NB patients treated with ch14.18/CHO is described and it is shown that neither eight freeze-thaw cycles nor storage at room temperature for up to 168h affected HACA stability in serum.
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
TLDR
Ch14.18/CHO-mediated effects upregulate the inhibitory immune checkpoint PD-1/PD-L1, and combination of ch14.
Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO
TLDR
Reduction of immune suppressive myeloid cells augments anti-NB efficacy of a ch14.18/CHO-based immunotherapy representing a new effective treatment strategy against GD2-positive cancers.
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
Effective treatment of high-risk neuroblastoma (NB) remains a major challenge in pediatric oncology. Human/mouse chimeric monoclonal anti-GD2 antibody (mAb) ch14.18 is emerging as a treatment option
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients
Purpose: This study aimed to assess the safety, pharmacokinetic and activity profiles of the human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 produced in Chinese hamster
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside
TLDR
The studies demonstrate the induction of ganglioside-specific T cell-dependent immunity by Ab2 in mice, and T cells showed specific reactivity to gangliosiside expressed by tumor cells.
Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2.
TLDR
Results suggest that the anti-Id 1A7 can induce GD2-specific IgG antibodies that can recognize cell surface-associated as well as soluble disialoganglioside GD2.
Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
TLDR
Future trials will attempt to enhance the antitumor response by the addition of interleukin 2, granulocyte macrophage colony-stimulating factor, and other cytokines, together with the 1A7 vaccine.
Anti-idiotype antibody vaccine therapy for cancer
TLDR
The greatest challenge of immunotherapy by means of anti- Id vaccines is to identify the optimal anti-Id antibody that will function as a true surrogate antigen for a TAA system, and ideally will generate both humoral and cellular immune responses.
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
TLDR
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma.
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
TLDR
In vivo depletion of NK-cells completely abrogated this effect, suggesting that the mechanism involved in the ch14.18/CHO induced anti-neuroblastoma effect is mediated by NK-dependent ADCC.
Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2
TLDR
To evaluate the efficiency of DNA vaccines encoding anti-idiotype antibodies, expression plasmids encoding the variable heavy (VH) and variable light (VL) chains of 1A7 were constructed and a ∼30-kDa protein was expressed by both configurations of the single-chain variable fragment.
Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
TLDR
It is shown that DNA immunization with pSA-MD may provide a useful strategy for active immunization against neuroblastoma and is consistent with superior calculated binding free energy, dissociation constant, and GD2 mimicry potential for GD2 mimotope MD over MA.
Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate
TLDR
Active GD2-KLH/MPL-A immunization was technically feasible, but did not elicit anti-GD2 antibody generation, despite high titres against the immunoadjuvants.
A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity
TLDR
Effective therapeutic vaccination against neuroblastoma with a novel rationally designed TH minigene vaccine without induction of autoimmunity is shown, providing an important baseline for future clinical application of this strategy.
...
1
2
3
...